- Home
- RNAC vs OABI Comparison
RNAC vs OABI Comparison
Compare RNAC & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAC
- OABI
- Stock Information
- Founded
- RNAC 2007
- OABI 2012
- Country
- RNAC United States
- OABI United States
- Employees
- RNAC N/A
- OABI N/A
- Industry
- RNAC Biotechnology: Pharmaceutical Preparations
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- RNAC Health Care
- OABI Health Care
- Exchange
- RNAC Nasdaq
- OABI Nasdaq
- Market Cap
- RNAC 242.4M
- OABI 198.2M
- IPO Year
- RNAC 2016
- OABI N/A
- Fundamental
- Price
- RNAC $9.92
- OABI $1.60
- Analyst Decision
- RNAC Strong Buy
- OABI Strong Buy
- Analyst Count
- RNAC 6
- OABI 3
- Target Price
- RNAC $41.25
- OABI $7.00
- AVG Volume (30 Days)
- RNAC 65.3K
- OABI 1.2M
- Earning Date
- RNAC 08-07-2025
- OABI 08-07-2025
- Dividend Yield
- RNAC N/A
- OABI N/A
- EPS Growth
- RNAC N/A
- OABI N/A
- EPS
- RNAC N/A
- OABI N/A
- Revenue
- RNAC $34,173,000.00
- OABI $26,744,000.00
- Revenue This Year
- RNAC N/A
- OABI N/A
- Revenue Next Year
- RNAC N/A
- OABI $45.65
- P/E Ratio
- RNAC N/A
- OABI N/A
- Revenue Growth
- RNAC 31.91
- OABI 27.07
- 52 Week Low
- RNAC $8.46
- OABI $1.22
- 52 Week High
- RNAC $29.65
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- RNAC 47.60
- OABI 54.70
- Support Level
- RNAC $9.72
- OABI $1.35
- Resistance Level
- RNAC $10.56
- OABI $1.81
- Average True Range (ATR)
- RNAC 0.67
- OABI 0.10
- MACD
- RNAC 0.07
- OABI 0.04
- Stochastic Oscillator
- RNAC 42.91
- OABI 71.96
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.